OliX PharmaceuticalsInc - Asset Resilience Ratio

Latest as of September 2025: 61.19%

OliX PharmaceuticalsInc (226950) has an Asset Resilience Ratio of 61.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 226950 total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

₩114.17 Billion
≈ $77.37 Million USD Cash + Short-term Investments

Total Assets

₩186.58 Billion
≈ $126.44 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2016–2024)

This chart shows how OliX PharmaceuticalsInc's Asset Resilience Ratio has changed over time. See OliX PharmaceuticalsInc (226950) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down OliX PharmaceuticalsInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OliX PharmaceuticalsInc (226950) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩114.17 Billion 61.19%
Total Liquid Assets ₩114.17 Billion 61.19%

Asset Resilience Insights

  • Very High Liquidity: OliX PharmaceuticalsInc maintains exceptional liquid asset reserves at 61.19% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

OliX PharmaceuticalsInc Industry Peers by Asset Resilience Ratio

Compare OliX PharmaceuticalsInc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for OliX PharmaceuticalsInc (2016–2024)

The table below shows the annual Asset Resilience Ratio data for OliX PharmaceuticalsInc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 11.96% ₩8.52 Billion
≈ $5.78 Million
₩71.25 Billion
≈ $48.28 Million
-1.59pp
2023-12-31 13.55% ₩13.93 Billion
≈ $9.44 Million
₩102.83 Billion
≈ $69.68 Million
-33.09pp
2022-12-31 46.64% ₩61.87 Billion
≈ $41.93 Million
₩132.65 Billion
≈ $89.90 Million
-10.77pp
2021-12-31 57.41% ₩49.76 Billion
≈ $33.72 Million
₩86.67 Billion
≈ $58.74 Million
-29.27pp
2020-12-31 86.68% ₩68.11 Billion
≈ $46.16 Million
₩78.58 Billion
≈ $53.25 Million
+42.54pp
2019-12-31 44.14% ₩19.95 Billion
≈ $13.52 Million
₩45.21 Billion
≈ $30.64 Million
-7.65pp
2018-12-31 51.79% ₩28.81 Billion
≈ $19.53 Million
₩55.64 Billion
≈ $37.70 Million
-0.51pp
2017-12-31 52.30% ₩11.32 Billion
≈ $7.67 Million
₩21.64 Billion
≈ $14.67 Million
-10.30pp
2016-12-31 62.60% ₩9.48 Billion
≈ $6.43 Million
₩15.15 Billion
≈ $10.27 Million
--
pp = percentage points

About OliX PharmaceuticalsInc

KQ:226950 Korea Biotechnology
Market Cap
$2.35 Billion
₩3.47 Trillion KRW
Market Cap Rank
#5669 Global
#145 in Korea
Share Price
₩172500.00
Change (1 day)
-6.55%
52-Week Range
₩34800.00 - ₩207000.00
All Time High
₩207000.00
About

OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more